Skip to main content
. 2022 Mar 8;4(3):otac007. doi: 10.1093/crocol/otac007

Figure 1.

Figure 1.

Disease severity at enrollment for patients with UC. *95% CI of mean difference in percentage points did not include 0. Abbreviations: 5-ASAs, 5-aminosalicylic acids; BIO/JAKi, biologics, Janus kinase inhibitors; UC, ulcerative colitis.